Difference between revisions of "Motesanib (AMG-706)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
Warner-admin (talk | contribs) m (Warner-admin moved page Motesanib (AMG 706) to Motesanib (AMG-706)) |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
==[[Thyroid cancer]]== | ==[[Thyroid cancer]]== | ||
| − | # Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. [https:// | + | # Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. [https://doi.org/10.1056/NEJMoa075853 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18596272/ PubMed] |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' AMG-706 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | + | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
[[Category:PDGFR inhibitors]] | [[Category:PDGFR inhibitors]] | ||
| Line 17: | Line 20: | ||
[[Category:RET inhibitors]] | [[Category:RET inhibitors]] | ||
| − | [[Category:Thyroid cancer medications]] | + | [[Category:Thyroid cancer, differentiated medications (investigational)]] |
| − | [[Category: | + | [[Category:Halted drugs]] |
Latest revision as of 12:30, 27 July 2023
Mechanism of action
From the NCI Drug Dictionary: The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors
Preliminary data
Thyroid cancer
- Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. link to original article PubMed
Also known as
- Code name: AMG-706